<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
enta-s8.DOCX.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 10, 2021</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REGISTRATION NO. 333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:center;text-indent:0%;font-weight:bold;font-style:normal;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br />Washington, D.C. 20549 </font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:center;text-indent:0%;font-weight:bold;font-style:normal;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">____________________</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:center;text-indent:0%;font-size:14pt;font-weight:bold;font-style:normal;letter-spacing:-0.1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">FORM S-8</font><font style="text-decoration:none;font-size:10pt;"><br />REGISTRATION STATEMENT UNDER<br />THE SECURITIES ACT OF 1933</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:center;text-indent:0%;font-weight:bold;font-style:normal;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">____________________</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:center;text-indent:0%;font-size:12pt;font-weight:bold;font-style:normal;letter-spacing:-0.1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">ENANTA PHARMACEUTICALS, INC.</font><font style="text-decoration:none;font-size:10pt;"><br /></font><font style="font-weight:normal;font-size:8pt;text-decoration:none;">(Exact name of registrant as specified in its charter) </font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:center;text-indent:0%;font-weight:bold;font-style:normal;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">____________________</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:88.68%;">
<tr>
<td style="width:44.87%;"></td>
<td style="width:43.8%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">Delaware&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">04-3205099</p></td>
</tr>
<tr>
<td valign="middle" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of incorporation or organization)</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer Identification No.)</p></td>
</tr>
<tr>
<td valign="middle" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">500 Arsenal Street, Watertown, MA</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">02472</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:center;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:center;text-indent:0%;font-weight:bold;font-style:normal;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">2019 Equity Incentive Plan</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:center;text-indent:0%;font-weight:normal;font-size:8pt;font-style:normal;letter-spacing:-0.1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">(Full title of the plan)</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:center;text-indent:0%;font-weight:bold;font-style:normal;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">____________________</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:center;text-indent:0%;font-weight:bold;font-style:normal;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">Jay R. Luly, Ph.D.<br />President and Chief Executive Officer<br />Enanta Pharmaceuticals, Inc.<br />500 Arsenal Street<br />Watertown, Massachusetts 02472<br /></font><font style="font-weight:normal;font-size:8pt;text-decoration:none;"> (Name and address of agent for service) </font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:center;text-indent:0%;font-weight:bold;font-style:normal;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">(617)&#160;607-0800</font><font style="font-weight:normal;text-decoration:none;"><br /></font><font style="font-weight:normal;font-size:8pt;text-decoration:none;">(Telephone number, including area code, of agent for service)</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:center;text-indent:0%;font-weight:bold;font-style:normal;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">____________________</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-align:center;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">Copy to: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:center;text-indent:0%;font-weight:bold;font-style:normal;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">Stacie S. Aarestad, Esq.<br />Foley Hoag LLP</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:center;text-indent:0%;font-weight:bold;font-style:normal;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">155 Seaport Boulevard<br />Boston, Massachusetts 02110-2600<br />(617)&#160;832-1000 </font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:center;text-indent:0%;font-weight:bold;font-style:normal;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">____________________</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.8%;">
<tr>
<td valign="top"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:auto;">
<p style="border-top:none 0pt;padding-top:1pt;border-left:none 0pt;padding-left:3pt;margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non&#8209;accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b&#8209;2 of the Exchange Act.</p>
<p style="text-align:justify;border-top:none 0pt;padding-top:1pt;border-bottom:none 0pt;padding-bottom:1pt;border-left:none 0pt;padding-left:3pt;margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:97.16%;">
<tr>
<td colspan="4" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:auto;">
<p style="border-top:none 0pt;padding-top:1pt;border-bottom:none 0pt;padding-bottom:1pt;border-left:none 0pt;padding-left:3pt;margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer <font style="font-size:10pt;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9745;</font></font></p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:auto;">
<p style="border-top:none 0pt;padding-top:1pt;border-bottom:none 0pt;padding-bottom:1pt;border-left:none 0pt;padding-left:3pt;margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer &#160;&#160;<font style="font-size:10pt;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:auto;">
<p style="border-top:none 0pt;padding-top:1pt;border-bottom:none 0pt;padding-bottom:1pt;border-left:none 0pt;padding-left:3pt;margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated&#160;filer&#160; &#160;<font style="font-size:10pt;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:auto;">
<p style="border-top:none 0pt;padding-top:1pt;border-bottom:none 0pt;padding-bottom:1pt;border-left:none 0pt;padding-left:3pt;margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;Reporting&#160;Company&#160;&#160;<font style="font-size:10pt;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;width:auto;">
<p style="border-top:none 0pt;padding-top:1pt;border-bottom:none 0pt;padding-bottom:1pt;border-left:none 0pt;padding-left:3pt;margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging Growth Company&#160; &#160;<font style="font-size:10pt;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p></td>
</tr>
</table></div>
<p style="border-top:none 0pt;padding-top:6pt;border-left:none 0pt;padding-left:21pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.49%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:3pt;margin-top:0pt;text-indent:2.14%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <font style="font-size:10pt;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-bottom:3pt;margin-top:0pt;text-indent:2.14%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CALCULATION OF REGISTRATION FEE</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:508.3pt;;">
<tr>
<td style="width:160.2pt;"></td>
<td style="width:94pt;"></td>
<td style="width:85.5pt;"></td>
<td style="width:98.5pt;"></td>
<td style="width:70.1pt;"></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title of each class of securities to be registered </p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amount to be registered(1)</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proposed maximum offering price per share(2)</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proposed maximum aggregate offering price(2)</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amount of registration fee</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, $0.01 par value</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">950,000 shares</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$50.00</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$47,500,000.00</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5,182.25</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Pursuant to Rule 416 under the Securities Act of 1933, to the extent that additional shares of the Registrant&#8217;s common stock may be issued or issuable as a result of a stock split or other distribution declared at any time by the Board of Directors of the Registrant while this Registration Statement is in effect, this Registration Statement is hereby deemed to cover all such additional shares of common stock.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Estimated solely for calculating the amount of the registration fee, pursuant to paragraphs (c) and (h) of Rule 457 under the Securities Act of 1933, as amended, the proposed maximum aggregate offering price is the product obtained by multiplying (i) $<font style="color:#000000;">50.00 </font>(the average of the high and low prices of the Registrant&#8217;s common stock on May <font style="color:#000000;">7</font>, 2021) by (ii) 950,000 (the number of additional shares of common stock issuable in connection with equity awards that may be granted in the future pursuant to the Enanta Pharmaceuticals, Inc. 2019 Equity Incentive Plan, as amended).</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:-3.85%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXPLANATORY NOTE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enanta Pharmaceuticals, Inc. (the &#8220;Registrant&#8221;) is filing this Registration Statement on Form S-8 (this &#8220;Registration Statement&#8221;) to register an additional 950,000 shares of its common stock, par value $0.01 per share, that may be issued and sold under the Enanta Pharmaceuticals, Inc. 2019 Equity Incentive Plan, as amended (the &#8220;Plan&#8221;), following the amendment to the Plan that was approved by the Registrant&#8217;s stockholders at its annual meeting on March 2, 2021. This Registration Statement is submitted in accordance with General Instruction E to Form S-8 regarding registration of additional securities, and pursuant to that instruction, the contents of the Registration Statement on Form S-8 (File No. 333-2321384) filed with the Securities and Exchange Commission on May 10, 2019 is incorporated herein by reference.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Part II</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:-0.22%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 8.&nbsp;&nbsp;Exhibits.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:478.8pt;;">
<tr>
<td style="width:63.9pt;"></td>
<td style="width:414.9pt;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br />Number</p></td>
<td valign="bottom" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:30.6pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Description</font></p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:30.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1177648/000119312513132679/d511662dex31.htm"><font style="text-decoration:underline;">Restated Certificate of Incorporation of Enanta Pharmaceuticals, Inc.&nbsp;&nbsp;Previously filed as Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8&#8209;K filed with the SEC on March 28, 2013 (File No.&#160;001-35839) and incorporated herein by reference</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:30.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1177648/000119312515294582/d95810dex32.htm"><font style="text-decoration:underline;">Amended and Restated Bylaws of Enanta Pharmaceuticals, Inc. (as amended and restated in August 2015).&nbsp;&nbsp;Previously filed as Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8&#8209;K filed with the SEC on August 18, 2015 (File No.&#160;001-35839) and incorporated herein by reference.</font></a></p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:30.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1177648/000119312513038960/d401292dex41.htm"><font style="text-decoration:underline;">Specimen certificate evidencing shares of common stock of Enanta Pharmaceuticals, Inc.&nbsp;&nbsp;Previously filed as Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-1/A filed with the SEC on February 5, 2013 (File No. 333-184779) and incorporated herein by reference.</font></a></p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="bottom" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:30.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="enta-ex51_7.htm"><font style="text-decoration:underline;">Opinion of Foley Hoag LLP.&nbsp;&nbsp;Filed herewith.</font></a></p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="bottom" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:30.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="enta-ex231_6.htm"><font style="text-decoration:underline;">Consent of PricewaterhouseCoopers LLP.&nbsp;&nbsp;Filed herewith.</font></a></p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.2</p></td>
<td valign="bottom" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:30.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="enta-ex51_7.htm"><font style="text-decoration:underline;">Consent of Foley Hoag LLP.&nbsp;&nbsp;Included in the opinion filed as Exhibit 5.1.</font></a></p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.1</p></td>
<td valign="bottom" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:30.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#POA"><font style="text-decoration:underline;">Power of Attorney.&nbsp;&nbsp;Included on the signature page hereto.</font></a></p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:30.6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1177648/000156459021011253/enta-ex101_37.htm"><font style="text-decoration:underline;">2019 Equity Incentive Plan (as amended March 2021).&nbsp;&nbsp;Previously filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on March 5, 2021 (File No. 001-35839) and incorporated herein by reference.</font></a></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Watertown, Commonwealth of Massachusetts, on May 10, 2021.</p>
<p style="margin-bottom:24pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENANTA PHARMACEUTICALS, INC.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;margin-left:36pt;"></font><font style="text-decoration:underline;">/s/ Jay R. Luly, Ph.D.</font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jay R. Luly, Ph.D.<br />President and Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="POA"></a>POWER OF ATTORNEY</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, the undersigned officers and directors of Enanta Pharmaceuticals, Inc., hereby severally constitute and appoint each of Jay R. Luly, Ph.D. and Paul J. Mellett, our true and lawful attorneys&#8209;in&#8209;fact, with full power to them in any and all capacities, to sign any and all amendments to this Registration Statement on Form S&#8209;8 (including any post&#8209;effective amendments thereto), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys&#8209;in&#8209;fact may do or cause to be done by virtue hereof.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:37.76%;"></td>
<td style="width:35.99%;"></td>
<td style="width:26.25%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Signature</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Title</font></p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;margin-right:5.13%;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Date</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Jay R. Luly, Ph.D.</font></p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jay R. Luly, Ph.D.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive <br />Officer and Director<br />(Principal Executive Officer)</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0.6pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 10, 2021</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; /s/ Paul J. Mellett</font></p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Paul J. Mellett</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer<br />(Principal Financial and<br />Accounting Officer)</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0.6pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 10, 2021</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Bruce L.A. Carter, Ph.D.</font></p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bruce L.A. Carter, Ph.D.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0.6pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 10, 2021</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Mark G. Foletta</font></p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark. G. Foletta</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0.6pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 10, 2021</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Kristine Peterson</font></p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kristine Peterson</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0.6pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 10, 2021</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">&nbsp;&nbsp;/s/ Lesley Russell, MBChB, MRCP</font></p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lesley Russell, MBChB., MRCP&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0.6pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 10, 2021</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;  /s/ Terry Vance</font></p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Terry Vance</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0.6pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 10, 2021</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "enta-s8.htm", "description": "S-8 2021", "secsgml_size_bytes": 51627}]
{"company-data": {"conformed-name": "ENANTA PHARMACEUTICALS INC", "cik": "0001177648", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-255957", "film-number": "21907265"}, "business-address": {"street1": "500 ARSENAL STREET", "city": "WATERTOWN", "state": "MA", "zip": "02472", "phone": "617 607 0800"}, "mail-address": {"street1": "500 ARSENAL STREET", "city": "WATERTOWN", "state": "MA", "zip": "02472"}}
enta-s8.DOCX.htm
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 10, 2021
REGISTRATION NO. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM S-8
REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933
____________________
ENANTA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
____________________
Delaware
04-3205099
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
500 Arsenal Street, Watertown, MA
(Address of Principal Executive Offices)
02472
(Zip Code)
2019 Equity Incentive Plan
(Full title of the plan)
____________________
Jay R. Luly, Ph.D.
President and Chief Executive Officer
Enanta Pharmaceuticals, Inc.
500 Arsenal Street
Watertown, Massachusetts 02472
(Name and address of agent for service)
(617) 607-0800
(Telephone number, including area code, of agent for service)
____________________
Copy to:
Stacie S. Aarestad, Esq.
Foley Hoag LLP
155 Seaport Boulevard
Boston, Massachusetts 02110-2600
(617) 832-1000
____________________
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non‑accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b‑2 of the Exchange Act.
Large accelerated filer
☑
Accelerated filer
☐
Non-accelerated filer
☐
Smaller Reporting Company
☐
Emerging Growth Company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
☐
CALCULATION OF REGISTRATION FEE
Title of each class of securities to be registered
Amount to be registered(1)
Proposed maximum offering price per share(2)
Proposed maximum aggregate offering price(2)
Amount of registration fee
Common Stock, $0.01 par value
950,000 shares
$50.00
$47,500,000.00
$5,182.25
(1)
Pursuant to Rule 416 under the Securities Act of 1933, to the extent that additional shares of the Registrant's common stock may be issued or issuable as a result of a stock split or other distribution declared at any time by the Board of Directors of the Registrant while this Registration Statement is in effect, this Registration Statement is hereby deemed to cover all such additional shares of common stock.
(
2
)
Estimated solely for calculating the amount of the registration fee, pursuant to paragraphs (c) and (h) of Rule 457 under the Securities Act of 1933, as amended, the proposed maximum aggregate offering price is the product obtained by multiplying (i) $
50.00
(the average of the high and low prices of the Registrant's common stock on May
7
, 2021) by (ii) 950,000 (the number of additional shares of common stock issuable in connection with equity awards that may be granted in the future pursuant to the Enanta Pharmaceuticals, Inc. 2019 Equity Incentive Plan, as amended).
EXPLANATORY NOTE
Enanta Pharmaceuticals, Inc. (the "Registrant") is filing this Registration Statement on Form S-8 (this "Registration Statement") to register an additional 950,000 shares of its common stock, par value $0.01 per share, that may be issued and sold under the Enanta Pharmaceuticals, Inc. 2019 Equity Incentive Plan, as amended (the "Plan"), following the amendment to the Plan that was approved by the Registrant's stockholders at its annual meeting on March 2, 2021. This Registration Statement is submitted in accordance with General Instruction E to Form S-8 regarding registration of additional securities, and pursuant to that instruction, the contents of the Registration Statement on Form S-8 (File No. 333-2321384) filed with the Securities and Exchange Commission on May 10, 2019 is incorporated herein by reference.
Part II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8.  Exhibits.
Exhibit
Number
Description
4.1
Restated Certificate of Incorporation of Enanta Pharmaceuticals, Inc.  Previously filed as Exhibit 3.1 to the Registrant's Current Report on Form 8‑K filed with the SEC on March 28, 2013 (File No. 001-35839) and incorporated herein by reference
.
4.2
Amended and Restated Bylaws of Enanta Pharmaceuticals, Inc. (as amended and restated in August 2015).  Previously filed as Exhibit 3.2 to the Registrant's Current Report on Form 8‑K filed with the SEC on August 18, 2015 (File No. 001-35839) and incorporated herein by reference.
4.3
Specimen certificate evidencing shares of common stock of Enanta Pharmaceuticals, Inc.  Previously filed as Exhibit 4.1 to the Registrant's Registration Statement on Form S-1/A filed with the SEC on February 5, 2013 (File No. 333-184779) and incorporated herein by reference.
5.1
Opinion of Foley Hoag LLP.  Filed herewith.
23.1
Consent of PricewaterhouseCoopers LLP.  Filed herewith.
23.2
Consent of Foley Hoag LLP.  Included in the opinion filed as Exhibit 5.1.
24.1
Power of Attorney.  Included on the signature page hereto.
99.1
2019 Equity Incentive Plan (as amended March 2021).  Previously filed as Exhibit 10.1 to the Registrant's Current Report on Form 8-K, filed with the SEC on March 5, 2021 (File No. 001-35839) and incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Watertown, Commonwealth of Massachusetts, on May 10, 2021.
ENANTA PHARMACEUTICALS, INC.
By:
/s/ Jay R. Luly, Ph.D.
Jay R. Luly, Ph.D.
President and Chief Executive Officer
POWER OF ATTORNEY
We, the undersigned officers and directors of Enanta Pharmaceuticals, Inc., hereby severally constitute and appoint each of Jay R. Luly, Ph.D. and Paul J. Mellett, our true and lawful attorneys‑in‑fact, with full power to them in any and all capacities, to sign any and all amendments to this Registration Statement on Form S‑8 (including any post‑effective amendments thereto), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys‑in‑fact may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.
Signature
Title
Date
/s/ Jay R. Luly, Ph.D.
Jay R. Luly, Ph.D.
President and Chief Executive
Officer and Director
(Principal Executive Officer)
May 10, 2021
/s/ Paul J. Mellett
Paul J. Mellett
Chief Financial Officer
(Principal Financial and
Accounting Officer)
May 10, 2021
/s/ Bruce L.A. Carter, Ph.D.
Bruce L.A. Carter, Ph.D.
Director
May 10, 2021
/s/ Mark G. Foletta
Mark. G. Foletta
Director
May 10, 2021
/s/ Kristine Peterson
Kristine Peterson
Director
May 10, 2021
/s/ Lesley Russell, MBChB, MRCP
Lesley Russell, MBChB., MRCP
Director
May 10, 2021
/s/ Terry Vance
Terry Vance
Director
May 10, 2021